• McKesson Corporation recently reported its fourth-quarter and fiscal 2026 results, with quarterly sales of US$96,295 million and net income of US$1,682 million, alongside full-year sales of US$403.43 billion and net income of US$4.76 billion, while continuing sizable share repurchases under its long-running buyback program.
• Beyond the headline numbers, McKesson is preparing to separate its Medical-Surgical Solutions segment and is bolstering capital returns, moves that could reshape how investors view the balance between its distribution operations and higher-margin healthcare services and technology platforms.
• Now, we’ll explore how McKesson’s Medical-Surgical separation plans and continued buybacks may influence its existing investment narrative and assumptions.

We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

McKesson Investment Narrative Recap

To own McKesson, you need to believe its scale in drug distribution and growing higher-margin services can offset pricing pressure and customer concentration. The latest results reinforce that story, while the Medical-Surgical separation and stepped-up buybacks do not radically change the near term focus on earnings growth and execution risk in specialty and oncology platforms.

The most relevant development here is McKesson’s intensified capital return program, including an extra US$5.0 billion in buyback authorization and a US$2.25 billion accelerated repurchase, alongside the Medical-Surgical separation progress. Together with fiscal 2026 earnings growth and fiscal 2027 guidance, these updates feed directly into how investors weigh McKesson’s core earnings power versus its exposure to large customers and evolving drug pricing policies.

Yet behind the solid headline numbers and capital returns, investors should also be aware of...

McKesson's narrative projects $499.3 billion revenue and $6.1 billion earnings by 2029.

Uncover how McKesson's forecasts yield a $951.73 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Five fair value estimates from the Simply Wall St Community span roughly US$2 to about US$952 per share, underscoring sharply different opinions on McKesson. Against that backdrop, McKesson’s push into higher margin oncology and specialty services, plus continued AI and automation investment, gives you several distinct narratives about where its earnings power could head next.

Explore 5 other fair value estimates on McKesson - why the stock might be worth less than half the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your McKesson research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free McKesson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate McKesson's overall financial health at a glance.

Curious About Other Options?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.